Please use this identifier to cite or link to this item:
Title: Targeting mitochondrial apoptosis to overcome treatment resistance in cancer
Authors: Ngoi N.Y.L.
Choong C.
Lee J.
Bellot G. 
Wong A.L.A. 
Goh B.C. 
Pervaiz S. 
Keywords: BCL-2
cancer therapeutics
targeted therapy
Issue Date: 1-Mar-2020
Publisher: MDPI AG
Citation: Ngoi N.Y.L., Choong C., Lee J., Bellot G., Wong A.L.A., Goh B.C., Pervaiz S. (2020-03-01). Targeting mitochondrial apoptosis to overcome treatment resistance in cancer. Cancers 12 (3) : 574-574. ScholarBank@NUS Repository.
Abstract: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Deregulated cellular apoptosis is a hallmark of cancer and chemotherapy resistance. The B-cell lymphoma 2 (BCL-2) protein family members are sentinel molecules that regulate the mitochondrial apoptosis machinery and arbitrate cell fate through a delicate balance between pro-and anti-apoptotic factors. The recognition of the anti-apoptotic BCL2 gene as an oncogenic driver in hematological malignancies has directed attention toward unraveling the biological significance of each of the BCL-2 superfamily members in cancer progression and garnered interest in the targeting of apoptosis in cancer therapy. Accordingly, the approval of venetoclax (ABT-199), a small molecule BCL-2 inhibitor, in patients with chronic lymphocytic leukemia and acute myeloid leukemia has become the proverbial torchbearer for novel candidate drug approaches selectively targeting the BCL-2 superfamily. Despite the inspiring advances in this field, much remains to be learned regarding the optimal therapeutic context for BCL-2 targeting. Functional assays, such as through BH3 profiling, may facilitate prediction of treatment response, development of drug resistance and shed light on rational combinations of BCL-2 inhibitors with other branches of cancer therapy. This review summarizes the pathological roles of the BCL-2 family members in cancer, discusses the current landscape of their targeting in clinical practice, and highlights the potential for future therapeutic inroads in this important area.
Source Title: Cancers
ISSN: 20726694
DOI: 10.3390/cancers12030574
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.pdfPublished version800.83 kBAdobe PDF




checked on Jun 25, 2022

Page view(s)

checked on Jun 23, 2022


checked on Jun 23, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.